Abstract
This multicenter phase II study evaluated the efficacy of the FEM regimen (5-fluorouracil 333 mg/m(2) each week, epirubicin 30 mg/m(2) once every 4 weeks and mitomycin-C 2.7 mg/m(2) once every 2 weeks) administered by hepatic artery infusion (HAI) for unresectable hepatic metastases of gastric cancer. The response rates were 55.6% (complete response: 3, partial response: 32, no change: 21, progressive disease: 7/63) and the mean 50% survival was 10.5 months. Most responders died due to the progression of extrahepatic lesions. HAI of the FEM regimen induced a high response rate in patients with hepatic metastases of gastric cancer, and the prognosis-determining factor was the existence of extrahepatic lesions in many patients.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Multicenter Study
MeSH terms
-
Aged
-
Antibiotics, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Epirubicin / administration & dosage
-
Female
-
Fluorouracil / administration & dosage
-
Hepatic Artery
-
Humans
-
Infusions, Intra-Arterial
-
Japan
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / secondary*
-
Male
-
Middle Aged
-
Mitomycin / administration & dosage
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / pathology*
-
Survival Analysis
-
Treatment Outcome
Substances
-
Antibiotics, Antineoplastic
-
Antimetabolites, Antineoplastic
-
Epirubicin
-
Mitomycin
-
Fluorouracil